Cargando…
Reversal Agents: What We Have and What We Can Expect
Clinical trials in patients with atrial fibrillation have demonstrated that non-vitamin K antagonist oral anticoagulants [novel oral anticoagulants (NOACs)] are markedly safer than warfarin with respect to serious bleeding—especially intracranial hemorrhage, the most feared and devastating complicat...
Autor principal: | Ruff, Christian T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MediaSphere Medical
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252789/ https://www.ncbi.nlm.nih.gov/pubmed/32477806 http://dx.doi.org/10.19102/icrm.2018.090403 |
Ejemplares similares
-
Artificial Intelligence in Urooncology: What We Have and What We Expect
por: Froń, Anita, et al.
Publicado: (2023) -
Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?
por: Torres, A., et al.
Publicado: (2014) -
Ketamine plus Alcohol: What We Know and What We Can Expect about This
por: Kobayashi, Natalia Harumi Correa, et al.
Publicado: (2022) -
Five decades of Fontan palliation: What have we learned? What should we expect?
por: Hassan, Adil, et al.
Publicado: (2023) -
Erratum to: Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?
por: Torres, A., et al.
Publicado: (2014)